Status: Recruiting
CLAiR Pivotal Study
This is a multi-site, observational clinical study to validate the performance of the CLAiR AI software in identifying elevated atherosclerotic cardiovascular disease (ASCVD) risk from retinal (eye) images obtained from two different retinal image camera models.
Participants needed: 942
Trial details
Age: 40-75Biological sex: AllType: ObservationalSponsor: Toku Eyes LtdUpdated: Mar 25, 2025Locations: 1
Eligibility criteria
Male or female, aged 40-75 years [+2]
Known history of atherosclerotic cardiovascular disease, including stroke, heart... [+5]